GSK 2245035

Drug Profile

GSK 2245035

Alternative Names: GSK-2245035

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Immunomodulators; Interferon alfa 2a stimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Allergic rhinitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Allergic-rhinitis in Netherlands (Intranasal, Spray)
  • 01 Dec 2016 Phase-II clinical trials in Allergic asthma in Germany, United Kingdom (Intranasal) (EudraCT2015-005645-31) (NCT02833974)
  • 12 Jul 2016 GlaxoSmithKline plans a phase II trial for Allergic asthma in Germany (Intranasal) (NCT02833974)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top